ArticleAnnals of nuclear medicine2021
High detection rate in [
Article in Annals of nuclear medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis.Prostate cancer and prostatic diseases · 2025Pooled it
- The Evolving Role of PSMA-PET/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact.Current oncology reports · 2025Pooled it
- Pooled it
- Diagnostic impact of interpretation criteria for [European journal of nuclear medicine and molecular imaging · 2026Article
- [International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Recent advances in theranostics and oncology PET: emerging radionuclides and targets.Annals of nuclear medicine · 2025Review
- The Role of 18F PSMA-1007 PET/CT in the Staging and Detection of Recurrence of Prostate Cancer, A Scoping Review.Cancers · 2025Review
- Whole-Body Bone Scan for Detecting Bone Metastasis in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era: A Retrospective Cohort Study of Post-Radical Prostatectomy Prostate Cancer Patients.Asia Oceania journal of nuclear medicine & biology · 2025Article
- PSMA PET/CT imaging and its application to prostate cancer treatment.Japanese journal of radiology · 2025Review
- [Diagnostics (Basel, Switzerland) · 2024Article
- Evaluation ofAnnals of nuclear medicine · 2024Article
- Preclinical Evaluation of Biodistribution and Toxicity of [International journal of molecular sciences · 2024Article
- Detection support of lesions in patients with prostate cancer usingInternational journal of computer assisted radiology and surgery · 2024Article
- Article
- Targeted α-therapy using astatine (European journal of nuclear medicine and molecular imaging · 2023Article
- The current status of prostate cancer treatment and PSMA theranostics.Therapeutic advances in medical oncology · 2023Review
- Diagnostic and prognostic significance of tartrate-resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: A real-world multi-institutional study.International journal of urology : official journal of the Japanese Urological Association · 2023Article
- Recurrent Prostate Cancer Diagnostics withDiagnostics (Basel, Switzerland) · 2022Review
- Biokinetics and dosimetry ofClinical physiology and functional imaging · 2022Article
- Predictors ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
objective
methodsWe enrolled a total of 28 patients (age 51-79 years) with BCR of prostate cancer. BCR was defined as a continuous increase in PSA after radical prostatectomy or radiation therapy without any apparent recurrent lesions on conventional diagnostic imaging (CT and bone scintigraphy). PSMA-PET scanning was performed approximately 60 min after intravenous injection of [
resultsAbnormal uptake, which was suspected to be recurrence or metastasis, was detected in 92.9% (26/28) of patients with BCR. The SUVmax was 8.4 ± 6.4 in local recurrence, 11.5 ± 11.8 in pelvic lymph nodes (LN), and 4.1 ± 1.6 in bone metastasis. The detection rates were 66.7% in the PSA group-1 (0.1-0.5 ng/mL), 85.7% in the PSA group-2 (0.5-1.0 ng/mL), and 100% in the PSA group-3 (above 1.0 ng/mL). Among the PET-positive BCR patients (n = 26), local recurrence was detected in 57.7% (15/26), pelvic LN in 42.3% (11/26), and bone metastasis in 15.4% (4/26). In 53% (8/15) of BCR patients who were suspected of local recurrence, focal uptake was detected adjacent to the bladder on [
conclusions[
trial registration(UMIN Clinical Trials Registry) UMIN000037697.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.